logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Hepatolenticular Degeneration

    FiltersReset Filters
    5 results

    • cuprimine

      (penicillamine)
      Bausch Health US, LLC
      Usage: CUPRIMINE is indicated for treating Wilson's disease, cystinuria, and severe, active rheumatoid arthritis unresponsive to conventional therapy. It is not effective for ankylosing spondylitis. Treatment aims to reduce copper accumulation, manage cystine levels, and improve rheumatoid arthritis symptoms when other therapies fail.

    • depen

      (Penicillamine)
      Meda Pharmaceuticals Inc.
      Usage: DEPEN is indicated for treating Wilson’s disease, cystinuria, and severe rheumatoid arthritis in patients who have not responded to conventional therapy. It helps minimize copper intake and promotes copper excretion in Wilson’s disease, reduces cystine excretion to prevent stone formation in cystinuria, and assists in managing severe rheumatoid arthritis.

    • galzin

      (Zinc Acetate)
      Eton Pharmaceuticals, Inc.
      Usage: Zinc acetate is indicated for the maintenance treatment of patients with Wilson’s disease who have previously received initial therapy with a chelating agent.

    • penicillamine

      (penicillamine)
      Par Pharmaceutical, Inc.
      Usage: Penicillamine tablets are indicated for treating Wilson’s disease, cystinuria, and severe rheumatoid arthritis that has not responded to conventional therapies. They aid in reducing copper accumulation in Wilson’s disease and managing cystine excretion in cystinuria, while use in rheumatoid arthritis is limited due to potential severe adverse reactions.

    • trientine hydrochloride

      (Trientine Hydrochloride)
      Actavis Pharma, Inc.
      Usage: Trientine hydrochloride is indicated for treating Wilson's disease in patients intolerant to penicillamine. It is not interchangeable with penicillamine and is not recommended for cystinuria, rheumatoid arthritis, or biliary cirrhosis. Clinical experience is limited, and alternate dosing regimens are not well-defined.